Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group, Multicenter Study With a 24-Week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin.

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group, Multicenter Study With a 24-Week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lixisenatide (Primary) ; Insulin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms GETGOAL-L
  • Sponsors Sanofi

Most Recent Events

  • 12 Feb 2023 Results from a pooled analysis of GetGoal-Duo 1, GetGoal-L, and GetGoal-L-C studies for type 2 diabetes in Asian patients were published in the Diabetes Therapy
  • 16 Jun 2020 Results of pooled analysis assessing the efficacy of LIXI vs. placebo as add-on treatment to BI plus minus metformin in Asian and Caucasian patients with T2DM presented at the 80th Annual Scientific Sessions of the American Diabetes Association
  • 27 Jul 2016 According to a Sanofi media release, lixisenatide (Adlyxin) has been approved by the US FDA for the treatment of adults with typre 2 diabetes based on results from GetGoal clinical program and ELIXA trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top